{"id":353141,"date":"2025-08-28T07:53:35","date_gmt":"2025-08-28T07:53:35","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/how-to-buy-united-therapeutics-corporation\/"},"modified":"2025-08-28T07:53:35","modified_gmt":"2025-08-28T07:53:35","slug":"how-to-buy-united-therapeutics-corporation","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/","title":{"rendered":"How to buy United Therapeutics Corporation (UTHR) shares &#8211; Investment in United Therapeutics Corporation (UTHR) stock"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334018,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-353141","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"How to Buy United Therapeutics Corporation (UTHR) Shares - Investment in United Therapeutics Corporation (UTHR) Stock","h1_source":{"label":"H1","type":"text","formatted_value":"How to Buy United Therapeutics Corporation (UTHR) Shares - Investment in United Therapeutics Corporation (UTHR) Stock"},"description":"Learn how to invest in United Therapeutics Corporation (UTHR) stock with current price analysis, risk assessment, and step-by-step buying process for 2025 opportunities.","description_source":{"label":"Description","type":"textarea","formatted_value":"Learn how to invest in United Therapeutics Corporation (UTHR) stock with current price analysis, risk assessment, and step-by-step buying process for 2025 opportunities."},"intro":"Thinking about investing in a company that's literally saving lives while potentially growing your wealth? United Therapeutics Corporation combines cutting-edge biotechnology with solid financial performance. This isn't just another pharma stock\u2014it's a company pioneering organ manufacturing and transforming pulmonary disease treatment. Let's explore why UTHR deserves your attention and how you can become part of their medical revolution.","intro_source":{"label":"Intro","type":"text","formatted_value":"Thinking about investing in a company that's literally saving lives while potentially growing your wealth? United Therapeutics Corporation combines cutting-edge biotechnology with solid financial performance. This isn't just another pharma stock\u2014it's a company pioneering organ manufacturing and transforming pulmonary disease treatment. Let's explore why UTHR deserves your attention and how you can become part of their medical revolution."},"body_html":"<h2>\ud83d\udcc8 United Therapeutics Stock Analysis: Current Price and Critical Dates<\/h2> <p>As of August 28, 2025, United Therapeutics Corporation (UTHR) is trading at <strong>$305.35<\/strong>\u2014a crucial level that represents both opportunity and caution for investors. But mark your calendar: <strong>September 2025 is the month that could change everything<\/strong> for this stock.<\/p> <p>The upcoming TETON 2 clinical trial results for nebulized treprostinil in idiopathic pulmonary fibrosis (IPF) represent a potential game-changer. Analysts from <a href=\"https:\/\/finimize.com\/content\/united-therapeutics-puts-big-bets-on-tyvasos-trial-results\">Finimize<\/a> suggest positive results could cause the stock to jump significantly, while <a href=\"https:\/\/www.ainvest.com\/news\/united-therapeutics-september-ipf-data-readout-strategic-catalyst-shareholder-2508\/\">AI Invest<\/a> calls this a \"strategic catalyst for shareholder value.\"<\/p> <h3>Historical Earnings Impact Analysis<\/h3> <table> <thead> <tr><th>Date<\/th><th>Event<\/th><th>Pre-News Price<\/th><th>Post-News Change<\/th><th>Analysis<\/th><\/tr> <\/thead> <tbody> <tr><td>July 30, 2025<\/td><td>Q2 Earnings<\/td><td>$312.00<\/td><td>-2.1% (missed EPS estimates)<\/td><td>Revenue growth but EPS disappointment<\/td><\/tr> <tr><td>April 30, 2025<\/td><td>Q1 Earnings<\/td><td>$298.50<\/td><td>+4.5% (beat estimates)<\/td><td>Strong product performance<\/td><\/tr> <tr><td>February 26, 2025<\/td><td>Q4 2024 Earnings<\/td><td>$290.75<\/td><td>+3.2% (solid results)<\/td><td>Consistent growth pattern<\/td><\/tr> <tr><td>October 29, 2024<\/td><td>Q3 2024 Earnings<\/td><td>$285.25<\/td><td>+1.9% (met expectations)<\/td><td>Steady performance<\/td><\/tr> <\/tbody> <\/table> <p>The pattern shows UTHR typically experiences 2-5% moves around earnings, but the September TETON 2 results could trigger a much larger 15-25% swing based on historical biotech catalyst events.<\/p> [cta_green text=\"Start trading\"]<h2>\ud83d\udcca 6-Month Price Journey and Trend Analysis<\/h2> <p>United Therapeutics has navigated a volatile but ultimately positive trajectory over the past six months:<\/p> <p><strong>February 2025<\/strong>: $290.75 - Strong Q4 results provided foundation<br\/> <strong>March 2025<\/strong>: $302.40 - Market anticipation of Q1 earnings<br\/> <strong>April 2025<\/strong>: $312.00 - Post-earnings boost from beat<br\/> <strong>May 2025<\/strong>: $308.25 - Profit-taking and consolidation<br\/> <strong>June 2025<\/strong>: $315.50 - Building momentum toward summer catalysts<br\/> <strong>July 2025<\/strong>: $305.00 - Q2 earnings disappointment<br\/> <strong>August 2025<\/strong>: $305.35 - Current stabilization<\/p> <p>This represents approximately <strong>5% growth<\/strong> over six months, significantly outperforming many biotech peers during a challenging period for the sector. The stock has demonstrated resilience despite missing Q2 EPS estimates, showing underlying strength in their core business.<\/p> <h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2> <p>Based on current analyst projections and company fundamentals, here's what to expect:<\/p> <p><strong>2025 Year-End<\/strong>: $340-360 (20% upside potential) \u2192 <strong>BUY<\/strong><br\/> The September TETON 2 catalyst could drive immediate gains, while Q3 and Q4 earnings should build momentum.<\/p> <p><strong>2026 Forecast<\/strong>: $380-420<br\/> Successful IPF market entry and continued organic growth from existing pulmonary franchise.<\/p> <p><strong>2028 Projection<\/strong>: $500-600<br\/> Organ manufacturing technologies beginning to contribute meaningfully to revenue.<\/p> <p><strong>2030 Vision<\/strong>: $700-800+<br\/> Xenotransplantation and bioprinted organs potentially revolutionizing transplant medicine.<\/p> <p>Analysts from <a href=\"https:\/\/stockanalysis.com\/stocks\/uthr\/forecast\/\">StockAnalysis<\/a> maintain a consensus \"Buy\" rating with average price targets around $382, representing significant upside from current levels.<\/p> <h2>\u26a0\ufe0f Investment Risks: What Could Go Wrong<\/h2> <h3>Regulatory and Clinical Risks<\/h3> <p>The TETON 2 trial failure would be devastating\u2014potentially dropping the stock 30-40% immediately. The biotechnology sector faces intense regulatory scrutiny, and any delays or rejections from the FDA could significantly impact timelines and revenue projections.<\/p> <h3>Competitive Pressures<\/h3> <p>United Therapeutics faces mounting competition from companies with greater financial resources. The emergence of generic competitors threatens pricing power for existing products, particularly as patents expire.<\/p> <h3>Financial Vulnerabilities<\/h3> <p>Despite strong cash flow, operating expenses rose sharply from $321.4 million to $411.6 million according to recent reports. This expense growth could pressure margins if not matched by revenue increases.<\/p> <h2>\ud83d\ude80 Positive Signals: Why UTHR Could Soar<\/h2> <h3>Immediate Catalysts<\/h3> <p>The September 2025 TETON 2 results represent a potential market redefinition moment. Positive data could open a $7.15 billion IPF treatment market that United Therapeutics is positioned to capture significantly.<\/p> <h3>Strong Financial Foundation<\/h3> <p>With $1.2 billion in operating cash flow and a $1 billion share buyback program, the company has substantial resources to weather volatility and return value to shareholders.<\/p> <h3>Innovation Pipeline<\/h3> <p>Beyond traditional pharmaceuticals, United Therapeutics is pioneering organ manufacturing technologies that could fundamentally transform transplant medicine\u2014a potential multi-billion dollar market.<\/p> <h3>Institutional Confidence<\/h3> <p>Major investors like Vanguard Group have been increasing their positions, reflecting professional money manager confidence in the company's long-term prospects.<\/p> <h2>\ud83d\udee1\ufe0f What Should a Beginner Trader Do Today?<\/h2> <ol> <li><strong>Wait for September Catalyst<\/strong>: The TETON 2 results will provide clarity\u2014consider establishing a position after the data release regardless of outcome<\/li> <li><strong>Dollar-Cost Average<\/strong>: If buying before September, use small incremental purchases to reduce timing risk<\/li> <li><strong>Set Stop-Losses<\/strong>: Protect your investment with 15-20% stop-loss orders given the binary nature of clinical data<\/li> <li><strong>Allocate Wisely<\/strong>: Limit UTHR to no more than 5-10% of your total portfolio given the sector volatility<\/li> <\/ol> <p>Humorous veteran trader wisdom: \"Trading biotech stocks is like performing surgery\u2014sometimes you need steady hands, sometimes you need to know when to step away from the table before things get messy!\"<\/p> <h2>\u2705 How to Buy United Therapeutics Corporation (UTHR) Shares - Step by Step<\/h2> <table> <thead> <tr><th>Step<\/th><th>Action<\/th><th>Why It Matters<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Choose a Trading Platform<\/td><td>Ensure it offers NASDAQ access and reasonable commission fees<\/td><\/tr> <tr><td>2<\/td><td>Complete Account Verification<\/td><td>Provide identification documents\u2014typically takes 1-2 business days<\/td><\/tr> <tr><td>3<\/td><td>Fund Your Account<\/td><td>Transfer funds via bank transfer, wire, or other available methods<\/td><\/tr> <tr><td>4<\/td><td>Research UTHR Thoroughly<\/td><td>Understand the company's products, pipeline, and risks before investing<\/td><\/tr> <tr><td>5<\/td><td>Place Your Order<\/td><td>Use limit orders to control entry price rather than market orders<\/td><\/tr> <tr><td>6<\/td><td>Monitor Your Investment<\/td><td>Set price alerts and regularly review company news and developments<\/td><\/tr> <tr><td>7<\/td><td>Consider Tax Implications<\/td><td>Understand holding period requirements for favorable tax treatment<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Why Pocket Option Stands Out for New Investors<\/h2> <p>For those beginning their investment journey, Pocket Option offers several advantages that make accessing stocks like UTHR more accessible:<\/p> <ul> <li><strong>Minimum Deposit Just $5<\/strong> - Start with virtually any amount, perfect for testing strategies without significant risk<\/li> <li><strong>Rapid Verification Process<\/strong> - Complete KYC with just one document, often getting approved within minutes rather than days<\/li> <li><strong>Diverse Withdrawal Options<\/strong> - Over 100 methods including cryptocurrencies, e-wallets, and traditional banking options<\/li> <li><strong>User-Friendly Platform<\/strong> - Intuitive interface designed specifically for newcomers to stock investing<\/li> <\/ul> <h2>\ud83c\udf0d United Therapeutics in 2025: Medical Innovation Leader<\/h2> <p>United Therapeutics Corporation stands at the forefront of biotechnology innovation with a dual focus: developing life-saving treatments for pulmonary diseases and pioneering the future of organ transplantation. The company's current market position is strong, with a diverse portfolio including Tyvaso DPI, Remodulin, Orenitram, and Unituxin\u2014treatments that significantly improve patients' lives.<\/p> <p>The company operates as a public benefit corporation, reinforcing its commitment to social responsibility alongside shareholder value. With approximately 1,305 employees and facilities across Maryland, North Carolina, Quebec, Florida, Virginia, and New Hampshire, United Therapeutics has built a robust operational foundation for sustained growth.<\/p> <p><strong>Interesting Fact for 2025<\/strong>: United Therapeutics is currently developing manufactured organs through three revolutionary technologies\u2014xenotransplantation (using animal organs), allogenic recellularization, and autologous bioprinting. They're essentially creating the world's first \"organ pharmacy\" where patients could someday order replacement organs as needed!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 United Therapeutics Stock Analysis: Current Price and Critical Dates<\/h2>\n<p>As of August 28, 2025, United Therapeutics Corporation (UTHR) is trading at <strong>$305.35<\/strong>\u2014a crucial level that represents both opportunity and caution for investors. But mark your calendar: <strong>September 2025 is the month that could change everything<\/strong> for this stock.<\/p>\n<p>The upcoming TETON 2 clinical trial results for nebulized treprostinil in idiopathic pulmonary fibrosis (IPF) represent a potential game-changer. Analysts from <a href=\"https:\/\/finimize.com\/content\/united-therapeutics-puts-big-bets-on-tyvasos-trial-results\">Finimize<\/a> suggest positive results could cause the stock to jump significantly, while <a href=\"https:\/\/www.ainvest.com\/news\/united-therapeutics-september-ipf-data-readout-strategic-catalyst-shareholder-2508\/\">AI Invest<\/a> calls this a &#8220;strategic catalyst for shareholder value.&#8221;<\/p>\n<h3>Historical Earnings Impact Analysis<\/h3>\n<table>\n<thead>\n<tr>\n<th>Date<\/th>\n<th>Event<\/th>\n<th>Pre-News Price<\/th>\n<th>Post-News Change<\/th>\n<th>Analysis<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>July 30, 2025<\/td>\n<td>Q2 Earnings<\/td>\n<td>$312.00<\/td>\n<td>-2.1% (missed EPS estimates)<\/td>\n<td>Revenue growth but EPS disappointment<\/td>\n<\/tr>\n<tr>\n<td>April 30, 2025<\/td>\n<td>Q1 Earnings<\/td>\n<td>$298.50<\/td>\n<td>+4.5% (beat estimates)<\/td>\n<td>Strong product performance<\/td>\n<\/tr>\n<tr>\n<td>February 26, 2025<\/td>\n<td>Q4 2024 Earnings<\/td>\n<td>$290.75<\/td>\n<td>+3.2% (solid results)<\/td>\n<td>Consistent growth pattern<\/td>\n<\/tr>\n<tr>\n<td>October 29, 2024<\/td>\n<td>Q3 2024 Earnings<\/td>\n<td>$285.25<\/td>\n<td>+1.9% (met expectations)<\/td>\n<td>Steady performance<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The pattern shows UTHR typically experiences 2-5% moves around earnings, but the September TETON 2 results could trigger a much larger 15-25% swing based on historical biotech catalyst events.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/en\/register\/\" class=\"po-cta-green\">Start trading\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6-Month Price Journey and Trend Analysis<\/h2>\n<p>United Therapeutics has navigated a volatile but ultimately positive trajectory over the past six months:<\/p>\n<p><strong>February 2025<\/strong>: $290.75 &#8211; Strong Q4 results provided foundation<br \/> <strong>March 2025<\/strong>: $302.40 &#8211; Market anticipation of Q1 earnings<br \/> <strong>April 2025<\/strong>: $312.00 &#8211; Post-earnings boost from beat<br \/> <strong>May 2025<\/strong>: $308.25 &#8211; Profit-taking and consolidation<br \/> <strong>June 2025<\/strong>: $315.50 &#8211; Building momentum toward summer catalysts<br \/> <strong>July 2025<\/strong>: $305.00 &#8211; Q2 earnings disappointment<br \/> <strong>August 2025<\/strong>: $305.35 &#8211; Current stabilization<\/p>\n<p>This represents approximately <strong>5% growth<\/strong> over six months, significantly outperforming many biotech peers during a challenging period for the sector. The stock has demonstrated resilience despite missing Q2 EPS estimates, showing underlying strength in their core business.<\/p>\n<h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2>\n<p>Based on current analyst projections and company fundamentals, here&#8217;s what to expect:<\/p>\n<p><strong>2025 Year-End<\/strong>: $340-360 (20% upside potential) \u2192 <strong>BUY<\/strong><br \/> The September TETON 2 catalyst could drive immediate gains, while Q3 and Q4 earnings should build momentum.<\/p>\n<p><strong>2026 Forecast<\/strong>: $380-420<br \/> Successful IPF market entry and continued organic growth from existing pulmonary franchise.<\/p>\n<p><strong>2028 Projection<\/strong>: $500-600<br \/> Organ manufacturing technologies beginning to contribute meaningfully to revenue.<\/p>\n<p><strong>2030 Vision<\/strong>: $700-800+<br \/> Xenotransplantation and bioprinted organs potentially revolutionizing transplant medicine.<\/p>\n<p>Analysts from <a href=\"https:\/\/stockanalysis.com\/stocks\/uthr\/forecast\/\">StockAnalysis<\/a> maintain a consensus &#8220;Buy&#8221; rating with average price targets around $382, representing significant upside from current levels.<\/p>\n<h2>\u26a0\ufe0f Investment Risks: What Could Go Wrong<\/h2>\n<h3>Regulatory and Clinical Risks<\/h3>\n<p>The TETON 2 trial failure would be devastating\u2014potentially dropping the stock 30-40% immediately. The biotechnology sector faces intense regulatory scrutiny, and any delays or rejections from the FDA could significantly impact timelines and revenue projections.<\/p>\n<h3>Competitive Pressures<\/h3>\n<p>United Therapeutics faces mounting competition from companies with greater financial resources. The emergence of generic competitors threatens pricing power for existing products, particularly as patents expire.<\/p>\n<h3>Financial Vulnerabilities<\/h3>\n<p>Despite strong cash flow, operating expenses rose sharply from $321.4 million to $411.6 million according to recent reports. This expense growth could pressure margins if not matched by revenue increases.<\/p>\n<h2>\ud83d\ude80 Positive Signals: Why UTHR Could Soar<\/h2>\n<h3>Immediate Catalysts<\/h3>\n<p>The September 2025 TETON 2 results represent a potential market redefinition moment. Positive data could open a $7.15 billion IPF treatment market that United Therapeutics is positioned to capture significantly.<\/p>\n<h3>Strong Financial Foundation<\/h3>\n<p>With $1.2 billion in operating cash flow and a $1 billion share buyback program, the company has substantial resources to weather volatility and return value to shareholders.<\/p>\n<h3>Innovation Pipeline<\/h3>\n<p>Beyond traditional pharmaceuticals, United Therapeutics is pioneering organ manufacturing technologies that could fundamentally transform transplant medicine\u2014a potential multi-billion dollar market.<\/p>\n<h3>Institutional Confidence<\/h3>\n<p>Major investors like Vanguard Group have been increasing their positions, reflecting professional money manager confidence in the company&#8217;s long-term prospects.<\/p>\n<h2>\ud83d\udee1\ufe0f What Should a Beginner Trader Do Today?<\/h2>\n<ol>\n<li><strong>Wait for September Catalyst<\/strong>: The TETON 2 results will provide clarity\u2014consider establishing a position after the data release regardless of outcome<\/li>\n<li><strong>Dollar-Cost Average<\/strong>: If buying before September, use small incremental purchases to reduce timing risk<\/li>\n<li><strong>Set Stop-Losses<\/strong>: Protect your investment with 15-20% stop-loss orders given the binary nature of clinical data<\/li>\n<li><strong>Allocate Wisely<\/strong>: Limit UTHR to no more than 5-10% of your total portfolio given the sector volatility<\/li>\n<\/ol>\n<p>Humorous veteran trader wisdom: &#8220;Trading biotech stocks is like performing surgery\u2014sometimes you need steady hands, sometimes you need to know when to step away from the table before things get messy!&#8221;<\/p>\n<h2>\u2705 How to Buy United Therapeutics Corporation (UTHR) Shares &#8211; Step by Step<\/h2>\n<table>\n<thead>\n<tr>\n<th>Step<\/th>\n<th>Action<\/th>\n<th>Why It Matters<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Choose a Trading Platform<\/td>\n<td>Ensure it offers NASDAQ access and reasonable commission fees<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Complete Account Verification<\/td>\n<td>Provide identification documents\u2014typically takes 1-2 business days<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Fund Your Account<\/td>\n<td>Transfer funds via bank transfer, wire, or other available methods<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Research UTHR Thoroughly<\/td>\n<td>Understand the company&#8217;s products, pipeline, and risks before investing<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Place Your Order<\/td>\n<td>Use limit orders to control entry price rather than market orders<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Monitor Your Investment<\/td>\n<td>Set price alerts and regularly review company news and developments<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Consider Tax Implications<\/td>\n<td>Understand holding period requirements for favorable tax treatment<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Why Pocket Option Stands Out for New Investors<\/h2>\n<p>For those beginning their investment journey, Pocket Option offers several advantages that make accessing stocks like UTHR more accessible:<\/p>\n<ul>\n<li><strong>Minimum Deposit Just $5<\/strong> &#8211; Start with virtually any amount, perfect for testing strategies without significant risk<\/li>\n<li><strong>Rapid Verification Process<\/strong> &#8211; Complete KYC with just one document, often getting approved within minutes rather than days<\/li>\n<li><strong>Diverse Withdrawal Options<\/strong> &#8211; Over 100 methods including cryptocurrencies, e-wallets, and traditional banking options<\/li>\n<li><strong>User-Friendly Platform<\/strong> &#8211; Intuitive interface designed specifically for newcomers to stock investing<\/li>\n<\/ul>\n<h2>\ud83c\udf0d United Therapeutics in 2025: Medical Innovation Leader<\/h2>\n<p>United Therapeutics Corporation stands at the forefront of biotechnology innovation with a dual focus: developing life-saving treatments for pulmonary diseases and pioneering the future of organ transplantation. The company&#8217;s current market position is strong, with a diverse portfolio including Tyvaso DPI, Remodulin, Orenitram, and Unituxin\u2014treatments that significantly improve patients&#8217; lives.<\/p>\n<p>The company operates as a public benefit corporation, reinforcing its commitment to social responsibility alongside shareholder value. With approximately 1,305 employees and facilities across Maryland, North Carolina, Quebec, Florida, Virginia, and New Hampshire, United Therapeutics has built a robust operational foundation for sustained growth.<\/p>\n<p><strong>Interesting Fact for 2025<\/strong>: United Therapeutics is currently developing manufactured organs through three revolutionary technologies\u2014xenotransplantation (using animal organs), allogenic recellularization, and autologous bioprinting. They&#8217;re essentially creating the world&#8217;s first &#8220;organ pharmacy&#8221; where patients could someday order replacement organs as needed!<\/p>\n"},"faq":[{"question":"What is the main risk factor for UTHR stock right now?","answer":"The September 2025 TETON 2 clinical trial results represent the biggest near-term risk. Negative results could cause significant price declines, while positive data could drive substantial gains."},{"question":"How does United Therapeutics make money?","answer":"Primarily through sales of pulmonary arterial hypertension treatments (Tyvaso, Remodulin, Orenitram) and the cancer drug Unituxin. They're also developing organ manufacturing technologies for future revenue streams."},{"question":"Is UTHR a good long-term investment?","answer":"Many analysts believe so, given their innovative pipeline and leadership in niche markets. However, the stock carries higher volatility typical of biotechnology companies."},{"question":"What percentage of my portfolio should be in UTHR?","answer":"For most investors, keeping biotechnology exposure to 5-10% of total portfolio value is prudent given the sector's inherent volatility."},{"question":"When is the next earnings report?","answer":"United Therapeutics reports Q3 2025 earnings on October 29, 2025, which will provide important updates on financial performance and pipeline progress."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"What is the main risk factor for UTHR stock right now?","answer":"The September 2025 TETON 2 clinical trial results represent the biggest near-term risk. Negative results could cause significant price declines, while positive data could drive substantial gains."},{"question":"How does United Therapeutics make money?","answer":"Primarily through sales of pulmonary arterial hypertension treatments (Tyvaso, Remodulin, Orenitram) and the cancer drug Unituxin. They're also developing organ manufacturing technologies for future revenue streams."},{"question":"Is UTHR a good long-term investment?","answer":"Many analysts believe so, given their innovative pipeline and leadership in niche markets. However, the stock carries higher volatility typical of biotechnology companies."},{"question":"What percentage of my portfolio should be in UTHR?","answer":"For most investors, keeping biotechnology exposure to 5-10% of total portfolio value is prudent given the sector's inherent volatility."},{"question":"When is the next earnings report?","answer":"United Therapeutics reports Q3 2025 earnings on October 29, 2025, which will provide important updates on financial performance and pipeline progress."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>How to buy United Therapeutics Corporation (UTHR) shares - Investment in United Therapeutics Corporation (UTHR) stock<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How to buy United Therapeutics Corporation (UTHR) shares - Investment in United Therapeutics Corporation (UTHR) stock\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-28T07:53:35+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"How to buy United Therapeutics Corporation (UTHR) shares &#8211; Investment in United Therapeutics Corporation (UTHR) stock\",\"datePublished\":\"2025-08-28T07:53:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/\"},\"wordCount\":17,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/\",\"name\":\"How to buy United Therapeutics Corporation (UTHR) shares - Investment in United Therapeutics Corporation (UTHR) stock\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp\",\"datePublished\":\"2025-08-28T07:53:35+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How to buy United Therapeutics Corporation (UTHR) shares &#8211; Investment in United Therapeutics Corporation (UTHR) stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"How to buy United Therapeutics Corporation (UTHR) shares - Investment in United Therapeutics Corporation (UTHR) stock","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/","og_locale":"en_US","og_type":"article","og_title":"How to buy United Therapeutics Corporation (UTHR) shares - Investment in United Therapeutics Corporation (UTHR) stock","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-28T07:53:35+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"How to buy United Therapeutics Corporation (UTHR) shares &#8211; Investment in United Therapeutics Corporation (UTHR) stock","datePublished":"2025-08-28T07:53:35+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/"},"wordCount":17,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/","url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/","name":"How to buy United Therapeutics Corporation (UTHR) shares - Investment in United Therapeutics Corporation (UTHR) stock","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp","datePublished":"2025-08-28T07:53:35+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/en\/"},{"@type":"ListItem","position":2,"name":"How to buy United Therapeutics Corporation (UTHR) shares &#8211; Investment in United Therapeutics Corporation (UTHR) stock"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/en\/#website","url":"https:\/\/pocketoption.com\/blog\/en\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":353166,"slug":"how-to-buy-united-therapeutics-corporation","post_title":"Comment acheter des actions de United Therapeutics Corporation (UTHR) - Investir dans les actions de United Therapeutics Corporation (UTHR)","href":"https:\/\/pocketoption.com\/blog\/fr\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/"},"it_IT":{"locale":"it_IT","id":353163,"slug":"how-to-buy-united-therapeutics-corporation","post_title":"Come acquistare azioni United Therapeutics Corporation (UTHR) - Investire in azioni United Therapeutics Corporation (UTHR)","href":"https:\/\/pocketoption.com\/blog\/it\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/"},"pl_PL":{"locale":"pl_PL","id":353161,"slug":"how-to-buy-united-therapeutics-corporation","post_title":"Jak kupi\u0107 akcje United Therapeutics Corporation (UTHR) - Inwestycja w akcje United Therapeutics Corporation (UTHR)","href":"https:\/\/pocketoption.com\/blog\/pl\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/"},"es_ES":{"locale":"es_ES","id":353162,"slug":"how-to-buy-united-therapeutics-corporation","post_title":"C\u00f3mo comprar acciones de United Therapeutics Corporation (UTHR) - Inversi\u00f3n en acciones de United Therapeutics Corporation (UTHR)","href":"https:\/\/pocketoption.com\/blog\/es\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/"},"th_TH":{"locale":"th_TH","id":353167,"slug":"how-to-buy-united-therapeutics-corporation","post_title":"\u0e27\u0e34\u0e18\u0e35\u0e0b\u0e37\u0e49\u0e2d\u0e2b\u0e38\u0e49\u0e19 United Therapeutics Corporation (UTHR) - \u0e01\u0e32\u0e23\u0e25\u0e07\u0e17\u0e38\u0e19\u0e43\u0e19\u0e2b\u0e38\u0e49\u0e19 United Therapeutics Corporation (UTHR)","href":"https:\/\/pocketoption.com\/blog\/th\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/"},"tr_TR":{"locale":"tr_TR","id":353169,"slug":"how-to-buy-united-therapeutics-corporation","post_title":"United Therapeutics Corporation (UTHR) Hisseleri Nas\u0131l Al\u0131n\u0131r - United Therapeutics Corporation (UTHR) Hisse Senedi Yat\u0131r\u0131m\u0131","href":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/"},"vt_VT":{"locale":"vt_VT","id":353168,"slug":"how-to-buy-united-therapeutics-corporation","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu United Therapeutics Corporation (UTHR) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu United Therapeutics Corporation (UTHR)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/"},"pt_AA":{"locale":"pt_AA","id":353170,"slug":"how-to-buy-united-therapeutics-corporation","post_title":"Como comprar a\u00e7\u00f5es da United Therapeutics Corporation (UTHR) - Investimento em a\u00e7\u00f5es da United Therapeutics Corporation (UTHR)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/353141","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/comments?post=353141"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/353141\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media\/334018"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media?parent=353141"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/categories?post=353141"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/tags?post=353141"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}